Scientific deep-dive
Which GLP-1 Has the Worst Side Effects?
A network meta-analysis of 33,354 people ranks the drugs symptom by symptom. Orforglipron — the oral pill — tops the nausea ranking, ahead of every injection.
Every GLP-1 causes gastrointestinal side effects, and until recently there was no way to compare them properly. A network meta-analysis of 33,354 adults with overweight or obesity and without diabetes now ranks them — and the drug with the highest nausea risk is the one people assume will be gentlest: orforglipron, the oral pill.[1]
The rankings
| Symptom | Which drugs raised the risk | Which did not |
|---|---|---|
| Nausea | All of them. Highest orforglipron, then exenatide, tirzepatide, semaglutide, liraglutide | — |
| Vomiting | Liraglutide, orforglipron, semaglutide, tirzepatide | Cagrilintide, exenatide |
| Diarrhea | Others in the analysis | Exenatide, cagrilintide, orforglipron |
| Constipation | Semaglutide, liraglutide | Cagrilintide, exenatide |
Nausea, vomiting, diarrhea and constipation were the most common gastrointestinal effects across the board, which will surprise nobody taking one. What is new is being able to say which drug is worse for which symptom.[1]
The oral pill is not the gentle option
The assumption that swallowing it instead of injecting it will be easier on the stomach is the opposite of what the data show.
Orforglipron came top for nausea and was among the drugs raising vomiting risk. That matters because it is the first approved oral non-peptide in this class and it is being marketed heavily on the convenience of a tablet — see our Foundayo article. Convenience of administration and gentleness on the gut are separate properties, and here they point in opposite directions.
It is worth noting the one place orforglipron did well: it was not associated with increased diarrhea risk. A drug can rank badly on one symptom and well on another, which is exactly why a single “tolerability” verdict is unhelpful.
How to use a ranking like this
- Match it to your own worst symptom. If constipation is what stopped you before, semaglutide and liraglutide are the two the analysis flagged. If vomiting is the problem, the picture is different again.
- Do not read it as a dose-matched comparison. Each drug was tested at its own doses in its own trials. A ranking of drugs is not a ranking of molecules at equivalent exposure.
- This is a non-diabetic population, deliberately. Rates and rankings differ in diabetes trials, where patients are often on other gastrointestinal-active drugs.
- Weight loss and side effects travel together. The drugs that do most tend to cause most, and a ranking that ignored efficacy would mislead.
Frequently Asked Questions
References
- 1.Ismaiel A, Scarlata GGM, Boitos I, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis International Journal of Obesity. 2025. PMID: 40804463.
Related research
GLP-1s and Inflammatory Bowel Disease
People with IBD were excluded from the pivotal trials, so the evidence is retrospective — 13 of 14 studies. It has not linked GLP-1s to more flares, and that null result deserves careful reading.
6 min read
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo — and by about the same amount whether or not the person had hypertension.
7 min read
Compounded GLP-1s and the Adverse Event Reports
A FAERS study found more adverse event reports for compounded GLP-1s. Reports are voluntary and there is no denominator — but one finding survives that critique, and it is about arithmetic.
6 min read
Do GLP-1 Drugs Reduce Dementia Risk? Three Analyses, Three Answers
A meta-analysis of 26 trials found a 45% reduction. A 396,963-patient cohort found 33%. A continuously updated BMJ review found nothing significant and graded its certainty low.
7 min read
Drinking on a GLP-1: What the Label Actually Says
The Wegovy label contains no guidance about drinking at all — we checked every one of its eleven uses of the word. What it does warn about, and what two randomized trials found when they tested the pairing deliberately.
8 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Oak
Semaglutide at $119/month, 37% under the register median
Pricing Compare
Get started →Direct Meds
Compounded semaglutide at $249/month
Pricing Compare
Get started →Try Ageless
Semaglutide at $119/month, 37% under the register median
Pricing Compare
Get started →